Brand refresh reflects growing industry focus on protecting patient affordability investments and improving visibility across the Gross-to-Net ecosystem

RIS Rx today announced a new brand identity and messaging platform reflecting its expanding role in addressing one of the pharmaceutical industry’s most persistent financial and operational challenges: Gross-to-Net (GTN) revenue leakage.

The refreshed brand centers on a discipline RIS Rx helped pioneer—real-time GTN Revenue Protection—which focuses on identifying and preventing GTN revenue leakage before it occurs.

For pharmaceutical manufacturers, the Gross-to-Net spread represents one of the largest and least transparent components of the income statement. PBM policies such as maximizers and accumulators, payer policies, pharmacy transactions, and patient eligibility rules can create blind spots that allow billions of dollars intended for patient affordability to be diverted or misapplied.

RIS Rx’s platform integrates into existing affordability and patient support ecosystems to provide real-time intervention, monitoring and analytics—before a patient’s first prescription fill. Through real-time patient segmentation and program verification, the company helps manufacturers ensure that affordability dollars are directed to the appropriate patients and programs at the moment they are needed.

“Pharmaceutical manufacturers are increasingly realizing that GTN is not just an accounting exercise—it’s an operational challenge that directly impacts patient access and brand performance,” said Gerard Rivera, CEO and Co-founder of RIS Rx. “Our mission is to bring integrity, visibility, and accountability to that process so manufacturers can ensure the support they allocate for patients actually reaches those patients.”

Founded by pharmacists, RIS Rx combines clinical expertise with advanced analytics to identify, prevent, and quantify GTN leakage across affordability programs. The company’s solutions bolt on seamlessly with existing copay vendors and hub providers, enabling rapid deployment with no disruption to patients or established workflows.

To date, RIS Rx has helped pharmaceutical manufacturers generate more than $1 billion in annual savings across brands and programs.

“Gross-to-Net has historically been managed through retrospective analysis and periodic audits,” said Stephen Hom, Co-founder, EVP and Chief Operating Officer of RIS Rx. “GTN Revenue Protection introduces a proactive model—one that enables manufacturers to identify and prevent leakage in real time, before those dollars are lost.”

RIS Rx provides manufacturers with real-time visibility into affordability program performance, continuous reporting, and compliance assurance, helping ensure that every dollar intended for patient support is used exactly as intended.

The company will roll out its refreshed brand across digital platforms, marketing materials, and industry engagements beginning this week.

About RIS Rx

RIS Rx is a healthcare technology company delivering real-time gross-to-net (GTN) revenue protection for the world’s leading pharmaceutical manufacturers. Through proprietary software, real-time analytics and pharmacist-led expertise, RIS Rx helps clients optimize operations, eliminate leakage and ensure that financial assistance reaches the patients who need it most. The company has protected more than $1 billion in annual revenue for its customers. Founded in 2020 and headquartered in Irvine, California, RIS Rx serves leading pharmaceutical manufacturers across a growing portfolio of drug brands. Learn more at www.RISRx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260317289617/en/

Pharmaceutical manufacturers are increasingly realizing that GTN is not just an accounting exercise—it’s an operational challenge that directly impacts patient access and brand performance.